High Hopes For Stent Antiplatelet Therapy Trial
This article was originally published in The Gray Sheet
Executive Summary
FDA, along with the four major drug-eluting stent manufacturers and four antiplatelet drug firms, are months away from launching an unprecedented $100 million, 20,000-patient trial to determine the optimum duration of dual antiplatelet therapy with drug-eluting stents
You may also be interested in...
FDA Contributes Funds To Industry Post-Stenting Antiplatelet Trial
FDA is contributing $1.5 million to a large, collaborative clinical study designed to find out the optimum length of time to give anti-clotting drugs to patients with coronary drug-eluting stents
FDA Contributes Funds To Industry Post-Stenting Antiplatelet Trial
The 20,000-patient dual antiplatelet therapy trial announced in October and slated to start enrolling patients this fall, likely will cost upward of $100 million, with most of the funds coming from industry.
FDA Contributes Funds To Industry Post-Stenting Antiplatelet Trial
FDA is contributing $1.5 million to a large, collaborative clinical study designed to find out the optimum length of time to give anti-clotting drugs to patients with coronary drug-eluting stents